Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of XTR006 PET imaging for brain tau (NFT) detection in elderly subjects
CTR20243763Phase 3Active
- Sponsor
- Sinotau Pharmaceutical Group
- Start
- Nov 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of florquinitau in Alzheimer's disease (AD), Mild Cognitive Impairment (MCI), sponsored by Sinotau Pharmaceutical Group. Started Nov 2024; status: active.
02
Drugs
florquinitau
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on CTR20243763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243763.